Emtora Biosciences is seeking a new CEO, as Carole Spangler Vaughn has left the company.
The company's board of directors decided to end its relationship with Spangler Vaughn because of "significant philosophical differences" between her and the board over the vision for the company, according to Emtora's Mark Horsey.
A search for a successor has begun. Meanwhile, Dan Hargrove, who was CEO prior to Spangler Vaughn, will serve
Emtora Biosciences is a clinical-stage biopharmaceutical company that develops and commercializes novel therapies for the treatment of cancer and genetic diseases.